Artwork
iconShare
 
Manage episode 374315463 series 2874357
Content provided by The Bioverge Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Bioverge Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
David Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify promising drug scaffolds to accelerate the development process.
  continue reading

43 episodes